Sugi Predict

Sugi Predict / Targets / CSNK1A1L

CSNK1A1L

Casein kinase I isoform alpha-like · Q8N752 · CSNK1A1L on Sugi Atlas →

987 patent compounds predicted against CSNK1A1L, 787 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15075603 SCHEMBL15075603 0.86 3/20
SCHEMBL19868925 SCHEMBL19868925 0.86 3/20
SCHEMBL4135600 SCHEMBL4135600 0.78 3/20
SCHEMBL4552997 SCHEMBL4552997 0.78 3/20
SCHEMBL178158 SCHEMBL178158 0.77 3/20
SCHEMBL2650684 SCHEMBL2650684 0.75 3/20
SCHEMBL4553479 SCHEMBL4553479 0.73 3/20
SCHEMBL20335253 SCHEMBL20335253 0.71 3/20
SCHEMBL4553131 SCHEMBL4553131 0.70 3/20
SCHEMBL7231228 SCHEMBL7231228 0.70 3/20
SCHEMBL1388020 SCHEMBL1388020 0.70 3/20
SCHEMBL2648503 SCHEMBL2648503 0.70 3/20
SCHEMBL2649542 SCHEMBL2649542 0.70 3/20
SCHEMBL4551864 SCHEMBL4551864 0.70 3/20
SCHEMBL4552833 SCHEMBL4552833 0.70 3/20
SCHEMBL7249555 SCHEMBL7249555 0.70 3/20
SCHEMBL9201698 SCHEMBL9201698 0.70 3/20
SCHEMBL14626484 SCHEMBL14626484 0.70 3/20
SCHEMBL19857269 SCHEMBL19857269 0.70 3/20
SCHEMBL20335254 SCHEMBL20335254 0.70 3/20

Clinical trials — most relevant to CSNK1A1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF) nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD) nanUNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders nanCOMPLETED
Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China nanUNKNOWN
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
IPSC Repository of Pediatric Cardiovascular Disease nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Delineation of Novel Monogenic Disorders in the United Arab Emirates Population nanUNKNOWN
Familial Investigations of Childhood Cancer Predisposition nanRECRUITING
Study of a Candidate Gene Involved in Goldenhar Syndrome. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK1A1L binder may also engage these)

ProteinNameSimilarity
P67962 — 1.000 P67962 →
P67963 — 1.000 P67963 →
B9VVJ6 — 0.996 B9VVJ6 →
Q8BK63 — 0.995 Q8BK63 →
CSNK1A1 Casein kinase I isoform alpha 0.995 landscape →
P67829 — 0.993 P67829 →
P67828 — 0.993 P67828 →
A0A0E0S0W9 — 0.992 A0A0E0S0W9 →
P42168 — 0.991 P42168 →
P40235 — 0.990 P40235 →
P67827 — 0.989 P67827 →
P97633 — 0.988 P97633 →
P54367 — 0.985 P54367 →
G5EI58 — 0.985 G5EI58 →
Q4R9A9 — 0.984 Q4R9A9 →
Q7T2E3 — 0.983 Q7T2E3 →
Q6P647 — 0.983 Q6P647 →
Q62761 — 0.982 Q62761 →
Q6QNL9 — 0.982 Q6QNL9 →
Q9DC28 — 0.980 Q9DC28 →
Q6P3K7 — 0.978 Q6P3K7 →
CSNK1G2 Casein kinase I isoform gamma-2 0.978 landscape →
Q6QNM1 — 0.977 Q6QNM1 →
Q5BP74 — 0.975 Q5BP74 →
P35508 — 0.975 P35508 →
CSNK1D Casein kinase I isoform delta 0.975 landscape →
Q8IHZ9 — 0.974 Q8IHZ9 →
Q5RC72 — 0.974 Q5RC72 →
Q8BVP5 — 0.973 Q8BVP5 →
Q9JMK2 — 0.973 Q9JMK2 →